Study of Eso-SPONGE for Treating Leaks After Upper Gastrointestinal Surgery (DRAIN Upper)
A Prospective Multicenter Trial Evaluating the Safety and Effectiveness of Eso-SPONGE for the Treatment of Anastomotic Leaks in the Upper Gastrointestinal Tract
To evaluate the safety and effectiveness of sponge-based Endoscopic Vacuum Therapy (EVT) using Eso-SPONGE for the treatment of anastomotic leaks in the upper gastrointestinal tract in a prospective multi-center study.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
The study is a prospective multi-center, single -arm study with treatment of up to 74 subjects at up to 10 clinical centers. Subjects who meet all eligibility criteria will receive the Eso-Sponge and up to 4 months follow-up.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Evelyne Ho, MPH, MBA
- Numero di telefono: 978-483-8856
- Email: evelyne.ho@bsci.com
Luoghi di studio
-
-
Texas
-
Dallas, Texas, Stati Uniti, 76246
- Baylor University Medical Center
-
Contatto:
- Steven G Leeds, MD
- Numero di telefono: 972-817-6050
- Email: Steven.leeds@bswhealth.org
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria
-
Confirmed Type II anastomotic leaks in the esophagus or stomach
- Type I: Leak requiring no change in treatment
- Type II: Leak requiring intervention but not surgery
- Type III: Leak requiring surgical intervention
-
Subject has an anastomotic leak in the esophagus or stomach that is endoscopically accessible within the range of the overtube length.
-
Subject is eligible for endoscopic intervention.
-
Subject has a transmural defect of at least 2 cm in diameter in the esophagus or stomach.
-
Subject understands the trial requirements and is willing and able to comply with the study procedures, all protocol-required follow up evaluations and provide written informed consent to participate in the study.
-
Investigator decision that EVT is the most suitable treatment of the available treatment options.
Exclusion Criteria:
- Subject is under 18 years of age.
- Potentially vulnerable subject, including, but not limited to pregnant women.
- Subject has undergone EVT or other similar interventions for the current leak.
- Subject had upper gastrointestinal surgery resulting in the leak more than 60 days prior to the planned study procedure.
- Subject has any necrotic tissue that would require endoscopic debridement prior to Eso-SPONGETM placement.
- Subject has known contraindication for EVT as per the Investigator Brochure (IB)
- Subject is currently enrolled in another investigational study that would directly interfere with the current study, without prior written approval from the sponsor.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Eso-Sponge(TM)
Patients who meet all the inclusion criteria and none of the exclusion criteria will have an Eso-Sponge(TM) placed for the treatment of anastomotic leaks in the upper gastrointestinal tract. |
Treatment of anastomotic leaks or perforations in the upper gastrointestinal tract by means of negative pressure including intraluminal or intracavitary therapy of paraoesophageal and mediastinal septic focus or localized abscesses that are endoscopically accessible within the range of the overtube length. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Serious Adverse Events
Lasso di tempo: Within 3-4 months
|
The proportion of subjects with one or more study device or endoscopic or study procedure-related serious adverse events (SAEs) occurring up to 3 months after the last study device removal. |
Within 3-4 months
|
|
Clinical Success
Lasso di tempo: 30-Days after study procedure
|
The proportion of subjects that demonstrate clinical success, which is defined as closure of the anastomotic leak or perforation in the upper GIT, confirmed via endoscopy or contrast-enhanced computed tomography imaging within 30 days after the study procedure without the need for an additional intervention. Note: Subjects without clinical success will be followed until the leak resolves or a permanent disease process stabilizes, up to 3 months post final sponge removal. |
30-Days after study procedure
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Technical Success
Lasso di tempo: 30-Days after study procedure
|
Defined as the ability to deploy the Eso-SPONGE in the intended position. This will be calculated for each study procedure and Eso-SPONGE Exchange. |
30-Days after study procedure
|
|
Closure Time
Lasso di tempo: 30-days after study procedure
|
Time to anastomotic leak closure from the surgery that led to the leak. |
30-days after study procedure
|
|
Closure Time
Lasso di tempo: Through end of study, up to 4 months
|
Time to leak closure from the initial study procedure. |
Through end of study, up to 4 months
|
|
Rate of Reinterventions
Lasso di tempo: Through study completion, an average of 3 to 4 months
|
Rate of Reinterventions after closure of the anastomotic leak. |
Through study completion, an average of 3 to 4 months
|
|
Time to Additional Intervention
Lasso di tempo: 30-days after study procedure
|
Time to additional intervention, if Eso-SPONGETM treatment is insufficient. |
30-days after study procedure
|
|
Leak Recurrence
Lasso di tempo: Through study completion, an average of 3 to 4 months
|
Anastomotic leak recurrence within 3-months following completion of Eso-SPONGETM therapy. |
Through study completion, an average of 3 to 4 months
|
|
Eso-SPONGE Exchanges
Lasso di tempo: 30-days after study procedure
|
Number of Eso-SPONGETM exchanges needed to reach clinical success. |
30-days after study procedure
|
|
Length of Hospitalization
Lasso di tempo: 30 days after study procedure
|
Length of Hospitalization during EVT treatment. |
30 days after study procedure
|
|
Mortality Rate
Lasso di tempo: Through study completion, an average of 3 to 4 months
|
Mortality rate through 3-month follow-up. |
Through study completion, an average of 3 to 4 months
|
|
Unplanned Hospital Re-admissions
Lasso di tempo: Through study completion, an average of 3 to 4 months
|
Unplanned hospital re-admission related to the leak within 90 days of initial discharge. |
Through study completion, an average of 3 to 4 months
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- E7211
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .